Highest-materiality recent filing
Hims & Hers names Jonathan M. Franklin chief accounting officer, succeeding Irene Becklund
Franklin began at Hims & Hers on October 5, 2026 and was appointed principal accounting officer effective October 9, 2026, concurrent with Irene Becklund's previously disclosed resignation.
Hims & Hers Q2 revenue up 38% to $753M; raises FY26 guidance to $3.1-3.3B
Q2 revenue $753.2M, +38% YoY; subscribers 2.89M, +19% YoY.
Irene Becklund resigns as Chief Accounting Officer and Principal Accounting Officer, effective October 9, 2026.
Hims & Hers enters $400M receivables purchase facility with JPMorgan, 364-day term
Receivables Purchase Agreement allows sale of eligible receivables up to $400M outstanding.
Hims & Hers annual meeting results: all nominees and proposals approved
Annual meeting held June 11, 2026; all nine director nominees elected with over 1.5B votes each.
Hims & Hers completes acquisition of Eucalyptus; reaffirms 2030 targets of $6.5B revenue
Acquisition closed, making Hims & Hers the world's largest consumer health platform.
Hims & Hers issues $402.5M of 0% convertible notes due 2032; enters capped calls
Issued $402.5M aggregate principal of 0.00% Convertible Senior Notes due June 1, 2032.
Hims & Hers prices $350M 0.00% convertible notes due 2032; funds Eucalyptus acquisition & AI
Offering upsized from $300M to $350M; initial purchasers can buy additional $52.5M.
Hims & Hers Q1 net loss $92.1M; revenue $608M (+4% YoY); raises FY2026 guidance to $2.8B-$3.0B
Revenue $608.1M (+4% YoY); net loss $92.1M vs net income $49.5M in Q1 2025.
Hims & Hers partners with Novo Nordisk, shifts US weight loss strategy to FDA-approved GLP-1s
Collaboration with Novo Nordisk to offer Ozempic and Wegovy on platform starting March 2026.
Hims & Hers FY2025 revenue up 59% to $2.35B, adj. EBITDA $318M; guides FY2026 rev $2.7-2.9B
Revenue $2.35B (+59% YoY); net income $128M; adj. EBITDA $318M vs $177M prior year.
Hims & Hers acquires Eucalyptus for up to $1.15B, expanding globally
Transaction valued up to $1.15B: ~$240M cash upfront, ~$710M deferred over 18 months, up to ~$200M earnouts.
Hims & Hers Health authorizes new $250M share repurchase program; prior $100M fully used
New $250M share repurchase program authorized by Board on Nov 13, 2025, expiring Nov 11, 2028.
Hims & Hers Q3 revenue $599M (+49% YoY), Adj. EBITDA $78.4M; narrows FY25 guidance
Q3 revenue $599M (+49% YoY), net income $15.8M (prior-year $75.6M included $60.8M tax benefit)
Hims & Hers COO Nader Kabbani transitions to advisory role; Mike Chi promoted to COO
Nader Kabbani steps into advisory role effective Nov 2, 2025, through July 2026.
No material event: Hims & Hers lists investor communication channels
Company updates list of official investor communication channels including websites and social media.
Hims & Hers signs 15-year lease for 352,012 sq ft Ohio facility
Lease for 352,012 sq ft in New Albany, OH, for office, R&D, lab, manufacturing, and pharmaceutical dispensing.
Hims & Hers Q2 rev $545M (+73%), net income $42.5M, reaffirms FY25
Revenue $544.8M (+73% YoY); net income $42.5M (vs $13.3M); Adj EBITDA $82.2M (vs $39.3M).
Hims & Hers shareholders elect directors, ratify KPMG, approve say-on-pay at 2025 annual meeting
All 10 director nominees elected; top vote-getter Kare Shcultz with 1.55B For; broker non-votes 55.9M shares.
$1.0B aggregate principal of 0.00% Convertible Senior Notes due 2030 issued May 13, 2025.
Hims & Hers prices $870M 0.00% convertible notes due 2030 for global expansion and AI investment
Initial $450M offering upsized to $870M; initial purchasers option for additional $130M.
Hims & Hers Q1 revenue $586M (+111% YoY), net income $49.5M, raises EBITDA guidance
Revenue $586M (+111% YoY); net income $49.5M (up 345% YoY); Adj. EBITDA $91.1M (up 182% YoY).
Hims & Hers COO Melissa Baird to step down, transition to advisory role
Baird will remain as COO until successor is identified and fully up to speed.
Hims & Hers FY2024 revenue $1.48B (+69% YoY); net income $126M vs loss; guides FY2025 rev $2.3-2.4B
Revenue $1.48B for FY2024, up 69% YoY; Q4 revenue $481M, up 95% YoY.
Hims & Hers appoints Deb Autor to board; board expands to ten
Board size increased from 9 to 10; Deb Autor appointed effective Nov 15, 2024.
Hims & Hers Q3 rev $401.6M (+77% YoY), net income $75.6M, raises FY guidance
Q3 2024: Revenue $401.6M (+77% YoY), net income $75.6M (vs -$7.6M), Adj EBITDA $51.1M.
Hims & Hers closes MedisourceRx acquisition; registers 976K shares for resale
Acquisition of Seaview Enterprises LLC (MedisourceRx) closed on September 5, 2024.
Hims & Hers Q2 revenue $315.6M (+52% YoY), turns profitable; raises FY outlook
Revenue $315.6M, up 52% YoY; subscribers 1.9M (+43% YoY).
Hims & Hers Health appoints Kåre Schultz to board, effective July 16, 2024
Board size increased from 8 to 9 to accommodate the newly created vacancy.
Hims & Hers stockholders elect all eight directors and ratify KPMG at 2024 annual meeting
All eight director nominees elected with >97% of votes cast; broker non-votes of 39M shares.
Hims & Hers appoints Anja Manuel to audit and risk committees
Director Anja Manuel added to audit and risk committees effective June 6, 2024.
Hims & Hers Q1 2024 revenue $278.2M (+46% YoY), net income $11.1M, raises FY guidance
Revenue $278.2M, up 46% YoY; net income $11.1M vs loss of $10.1M a year ago.
Hims & Hers appoints Christopher Payne to compensation and risk committees
Christopher Payne was elected to the Board effective March 30, 2024.
Hims & Hers appoints Anja Manuel to board, expanding to 11 directors
Board increased from 10 to 11 directors; Anja Manuel appointed effective April 24, 2024.
Hims & Hers appoints Christopher Payne to board of directors
Board expanded from 9 to 10; Christopher Payne, 55, appointed effective March 30, 2024.
Hims & Hers FY2023 revenue $872M (+65% YoY); Q4 net income $1.2M; guides FY2024 rev $1.17-1.20B
FY2023 revenue $872.0M, up 65% YoY; net loss improved to $(23.5)M from $(65.7)M.
Hims & Hers Q3 revenue $226.7M (+57% YoY), adjusted EBITDA $12.3M; raises FY outlook
Revenue of $226.7M for Q3 2023, up 57% YoY from $144.8M; net loss narrowed to $7.6M from $18.8M.
Hims & Hers Q2 revenue up 83% to $207.9M; raises FY 2023 guidance
Revenue $207.9M, up 83% YoY; net loss narrowed to $7.2M from $19.7M.
All director nominees elected, KPMG ratified, say-on-pay approved at annual meeting
All nine director nominees elected with over 1.5 billion votes in favor each; no opposition to any.
Hims & Hers Q1 revenue up 88% to $190.8M; raises FY2023 guidance
Revenue $190.8M (+88% YoY); net loss narrowed to $10.1M from $16.3M; adj. EBITDA $6.1M vs -$6.1M.
Hims & Hers Q4 revenue $167.2M (+97% YoY); achieves first positive adjusted EBITDA of $3.9M
Q4 revenue $167.2M, up 97% YoY; full year revenue $526.9M, up 94% YoY.
Hims & Hers appoints Christiane Pendarvis to board of directors
Board expanded from 10 to 11 directors; Pendarvis fills newly created vacancy effective Feb 16, 2023.
Revenue of $144.8M, up 95% YoY; net loss $(18.8)M vs $(15.9)M a year ago.
Hims & Hers Q2 revenue $113.6M (+87% YoY); raises FY22 revenue guidance to $470-485M
Revenue of $113.6M, up 87% YoY; net loss $(19.7M) vs $(9.2M) prior year.
Hims & Hers stockholders approve all proposals at 2022 annual meeting
Elected ten directors, including CEO Andrew Dudum, with over 1.5B votes each; broker non-votes ~41.4M.
Hims & Hers Q1 revenue $101.3M (+94% YoY); raises FY2022 guidance to $410-425M
Revenue $101.3M, up 94% YoY; net loss improved to $(16.3)M from $(51.4)M.
Hims & Hers conducts non-deal roadshow with investor deck; no material updates
Management held non-deal roadshow meetings with investors on March 29-30, 2022.
Hims & Hers Q4 revenue $84.7M (+104% YoY); FY2021 revenue $271.9M; guides FY2022 rev $365-380M
Q4 2021 revenue $84.7M (+104% YoY); net loss $(31.2)M vs $(5.2)M loss in Q4 2020.
Hims & Hers recasts 2020 & 2019 financials for reverse recapitalization
Recast audited consolidated financial statements for years ended Dec 31, 2020 and 2019.
Hims & Hers appoints new CFO Oluyemi Okupe, adds Dr. Patrick Carroll to board
Appointed Oluyemi Okupe as CFO effective Jan 24, 2022; previously CFO of Hipcamp, divisional CFO at Uber and Braintree.
On October 7, 2026, the Company's board of directors appointed Mr. Franklin as principal accounting officer of the Company, effective October 9, 2026, concurrently with the previously disclosed resignation of Irene Becklund as the Company's principal accounting officer.
On October 7, 2026, the Company's board of directors appointed Mr. Franklin as principal accounting officer of the Company, effective October 9, 2026, concurrently with the previously disclosed resignation of Irene Becklund as the Company's principal accounting officer.
On October 5, 2026, Jonathan M. Franklin commenced employment with Hims & Hers Health, Inc. (the “Company”) as chief accounting officer.
On July 13, 2026, Irene Becklund informed Hims & Hers Health, Inc. (the “Company”) of her intention to resign as Chief Accounting Officer and Principal Accounting Officer, effective as of October 9, 2026.
Melissa Baird, Chief Operating Officer of Hims & Hers Health, Inc. (the “Company”), announced her intention to transition into an advisory role with Hims & Hers in the coming months.
On November 15, 2024, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from nine to ten directors and appointed Deb Autor, 57, to fill the newly created vacancy, effective immediately.
On April 24, 2024, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from ten to eleven directors and appointed Anja Manuel, 49, to fill the newly created vacancy, effective immediately.
On March 30, 2024, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from nine to ten directors and appointed Christopher Payne, 55, to fill the newly created vacancy, effective March 30, 2024.
appointed Christiane Pendarvis, 52, to fill the newly created vacancy, effective February 16, 2023.
Irene Becklund, the Company’s controller, who is serving as interim principal financial officer and principal accounting officer as disclosed in the Company’s Current Report on Form 8-K filed on November 18, 2021, will continue as the Company’s principal accounting officer but will cease serving as interim principal financial officer upon the effectiveness of Mr. Okupe’s appointment.
On January 18, 2022, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) appointed Oluyemi Okupe as chief financial officer and principal financial officer of the Company, effective January 24, 2022.
appointed Dr. Patrick Carroll, M.D., 63
Max materiality 0.85 · Median 0.65 · Most common event earnings